Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Approves Plan to Include Hepatitis B Vaccines in Public Vaccination Programs
January 16, 2015
- 1.9 Billion Yen Allocated to Speed Up Regulatory Reviews
January 15, 2015
- 124.8 Billion Yen Earmarked in FY2015 Budget for AMED
January 15, 2015
- AJMC to Announce Guidelines for Investigator-Led Clinical Trials Next Month
January 15, 2015
- Japan Govt OKs FY2015 Tax Reform Plan
January 15, 2015
- Editor’s Pick: Five Healthcare News Headlines for Dec. 29 - Jan. 11
January 14, 2015
- Cabinet OKs Extra Budget, 3.5 Billion Yen Allocated for IFN-Free Treatment
January 13, 2015
- Panel Agrees to Add Hepatitis B Vaccines to Public Immunization Program
January 13, 2015
- MHLW Calls for Revision of Package Inserts for SGLT-2 Inhibitors
January 13, 2015
- FY2015 Budget to Earmark 47 Billion Yen to Promote Healthcare R&D
January 9, 2015
- PAFSC 2nd Committee to Discuss Eisai’s Anticancer Agent on Jan. 21
January 9, 2015
- 30% R&D Tax Deduction Cap Could Be Secured with Open Innovation Tax Break: Economic Affairs Division
January 8, 2015
- 2015 to Be “Starting Year for Major Reform” of Healthcare and Nursing Insurance Systems: Health Minister
January 8, 2015
- Public Trust Indispensable for Industry Development: Mr Futagawa of Health Policy Bureau
January 7, 2015
- Pharmaceutical and Food Safety Bureau to Promote Prescription-to-OTC Switches Based on Industry Opinions
January 6, 2015
- MHLW OKs 31 Products Including Takeda’s Vonoprazan
January 5, 2015
- Ruling Parties Settle on 25%-Plus-5% Cap for R&D Tax Credit
January 5, 2015
- Health Minister Shiozaki Reappointed
December 25, 2014
- LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
- Integrated Clinical and Epidemiological Research Ethical Guidelines to Take Effect April: MHLW
December 25, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…